Ad Comm votes 15-1 in favor of HyQvia

The FDA's Blood Products Advisory Committee votes 15-1 supporting the risk/benefit profile of Baxter's (BAX -1.7%HyQvia [Immune Globulin 10% (Human) with Recombinant Human Hyaluronidase].

The product was approved in Europe in 2013 for the treatment of adult patients with primary immunodeficiency syndromes and myeloma or chronic lymphocytic leukemia with severe secondary hypogammaglobinemia and recurrent infections.

The company expects an FDA decision this quarter.

Related ticker: (HALO +6.2%)

From other sites
Comments (1)
  • vector2
    , contributor
    Comments (22) | Send Message
    uhh, maybe mention that the relevant stocks are BAX and HALO?
    31 Jul 2014, 02:23 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs